Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy

Roberto Gallego-Pinazo, Rosa Dolz-Marco, Diamar Pardo-López, J Fernando Arevalo, Manuel Díaz-Llopis

Research output: Contribution to journalArticle

Abstract

Aim: To evaluate the efficacy of intravitreal injections of ranibizumab in adult-onset foveomacular vitelliform dystrophy (AOFVD). Methods: Six female patients were misdiagnosed in the office as occult choroidal neovascularization due to AMD, and scheduled for 3-monthly intravitreal injections of ranibizumab. One month after the third injection, all patients underwent further examinations consisting of visual acuity, optical coherence tomography, Indocyanine Green angiography, electrophysiological tests (electroretinogram and electrooculogram), and an exhaustive familial history of macular diseases. Cases were followed-up every 6 weeks since the formal diagnose of AOFVD was evidenced. Results: The mean BCVA improved from 0.36 ± 0.1 at baseline to 0.56 ± 0.1 (p=0.038). No significant change was evidence in the SD-OCT thickness analysis. Metamorphopsia disappeared completely in all cases after the first injection. No familial history was evidenced. Conclusions: Ranibizumab intravitreal injections are effective in the short-term BCVA improvement in patients with AOFVD.

Original languageEnglish (US)
Pages (from-to)455-458
Number of pages4
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume249
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Vitelliform Macular Dystrophy
Intravitreal Injections
Electrooculography
Choroidal Neovascularization
Injections
Indocyanine Green
Vision Disorders
Optical Coherence Tomography
Diagnostic Errors
Visual Acuity
Ranibizumab
Angiography
History

Keywords

  • Adult-onset foveomacular vitelliform dystrophy
  • Macular dystrophy
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy. / Gallego-Pinazo, Roberto; Dolz-Marco, Rosa; Pardo-López, Diamar; Arevalo, J Fernando; Díaz-Llopis, Manuel.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 249, No. 3, 03.2011, p. 455-458.

Research output: Contribution to journalArticle

Gallego-Pinazo, Roberto ; Dolz-Marco, Rosa ; Pardo-López, Diamar ; Arevalo, J Fernando ; Díaz-Llopis, Manuel. / Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy. In: Graefe's Archive for Clinical and Experimental Ophthalmology. 2011 ; Vol. 249, No. 3. pp. 455-458.
@article{29d0eaba900c46dc9ac34f5d6fa1ac11,
title = "Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy",
abstract = "Aim: To evaluate the efficacy of intravitreal injections of ranibizumab in adult-onset foveomacular vitelliform dystrophy (AOFVD). Methods: Six female patients were misdiagnosed in the office as occult choroidal neovascularization due to AMD, and scheduled for 3-monthly intravitreal injections of ranibizumab. One month after the third injection, all patients underwent further examinations consisting of visual acuity, optical coherence tomography, Indocyanine Green angiography, electrophysiological tests (electroretinogram and electrooculogram), and an exhaustive familial history of macular diseases. Cases were followed-up every 6 weeks since the formal diagnose of AOFVD was evidenced. Results: The mean BCVA improved from 0.36 ± 0.1 at baseline to 0.56 ± 0.1 (p=0.038). No significant change was evidence in the SD-OCT thickness analysis. Metamorphopsia disappeared completely in all cases after the first injection. No familial history was evidenced. Conclusions: Ranibizumab intravitreal injections are effective in the short-term BCVA improvement in patients with AOFVD.",
keywords = "Adult-onset foveomacular vitelliform dystrophy, Macular dystrophy, Ranibizumab",
author = "Roberto Gallego-Pinazo and Rosa Dolz-Marco and Diamar Pardo-L{\'o}pez and Arevalo, {J Fernando} and Manuel D{\'i}az-Llopis",
year = "2011",
month = "3",
doi = "10.1007/s00417-010-1536-1",
language = "English (US)",
volume = "249",
pages = "455--458",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0721-832X",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy

AU - Gallego-Pinazo, Roberto

AU - Dolz-Marco, Rosa

AU - Pardo-López, Diamar

AU - Arevalo, J Fernando

AU - Díaz-Llopis, Manuel

PY - 2011/3

Y1 - 2011/3

N2 - Aim: To evaluate the efficacy of intravitreal injections of ranibizumab in adult-onset foveomacular vitelliform dystrophy (AOFVD). Methods: Six female patients were misdiagnosed in the office as occult choroidal neovascularization due to AMD, and scheduled for 3-monthly intravitreal injections of ranibizumab. One month after the third injection, all patients underwent further examinations consisting of visual acuity, optical coherence tomography, Indocyanine Green angiography, electrophysiological tests (electroretinogram and electrooculogram), and an exhaustive familial history of macular diseases. Cases were followed-up every 6 weeks since the formal diagnose of AOFVD was evidenced. Results: The mean BCVA improved from 0.36 ± 0.1 at baseline to 0.56 ± 0.1 (p=0.038). No significant change was evidence in the SD-OCT thickness analysis. Metamorphopsia disappeared completely in all cases after the first injection. No familial history was evidenced. Conclusions: Ranibizumab intravitreal injections are effective in the short-term BCVA improvement in patients with AOFVD.

AB - Aim: To evaluate the efficacy of intravitreal injections of ranibizumab in adult-onset foveomacular vitelliform dystrophy (AOFVD). Methods: Six female patients were misdiagnosed in the office as occult choroidal neovascularization due to AMD, and scheduled for 3-monthly intravitreal injections of ranibizumab. One month after the third injection, all patients underwent further examinations consisting of visual acuity, optical coherence tomography, Indocyanine Green angiography, electrophysiological tests (electroretinogram and electrooculogram), and an exhaustive familial history of macular diseases. Cases were followed-up every 6 weeks since the formal diagnose of AOFVD was evidenced. Results: The mean BCVA improved from 0.36 ± 0.1 at baseline to 0.56 ± 0.1 (p=0.038). No significant change was evidence in the SD-OCT thickness analysis. Metamorphopsia disappeared completely in all cases after the first injection. No familial history was evidenced. Conclusions: Ranibizumab intravitreal injections are effective in the short-term BCVA improvement in patients with AOFVD.

KW - Adult-onset foveomacular vitelliform dystrophy

KW - Macular dystrophy

KW - Ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=79955628613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955628613&partnerID=8YFLogxK

U2 - 10.1007/s00417-010-1536-1

DO - 10.1007/s00417-010-1536-1

M3 - Article

C2 - 20931215

AN - SCOPUS:79955628613

VL - 249

SP - 455

EP - 458

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0721-832X

IS - 3

ER -